Publications by authors named "G Brufman"

Claim this Profile
C
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.
I G Ron, N Wigler, R Borovik, G Brufman, S Rizel

Am J Clin Oncol· August 2001

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
O Lyass, B Uziely, R Ben-Yosef, D Tzemach, N I Heshing, G Brufman

Cancer· September 2000

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

J Clin Oncol· November 1998

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

J Clin Oncol· January 1998

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.
G Brufman, E Colajori, N Ghilezan, M Lassus, A Martoni

Ann Oncol· February 1997

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis